Structure Therapeutics Inc.
GPCRHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs. At a $2.88B market cap, Structure Therapeutics Inc. ranks as a mid-cap company within healthcare. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Market Cap
$2.88B
Beta
-1.52
P/E (TTM)
—
P/E (Fwd)
-19.22
EPS (TTM)
$-3.03
EPS (Fwd)
$-2.10
ROE
-20.2%
ROA
-14.9%
Cash
$1.34B
Total Debt
$6.2M
Free CF
-$119.1M
52W Change
126.6%
Annual Financials
Cash vs Debt
Where GPCR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GPCR finished 7.67% below its 150-day moving average ($51.77) and 11.92% below its 200-day moving average ($54.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GPCR overbought or oversold?
At the September 3, 2026 close, GPCR's RSI(14) was 24.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Structure Therapeutics Inc. holds $1.34B in cash against $6.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$119.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -20.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -1.52 suggests GPCR is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, GPCR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GPCR.